Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic
syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly …

In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a leading cause of
chronic liver disease and cirrhosis, as well as an important risk factor for hepatocellular …

Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general
population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to …

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and
there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been …

Colostrum is the milk produced during the first few days after birth and contains high levels
of immunoglobulins, antimicrobial peptides, and growth factors. Colostrum is important for …

The emerging evidence on the interconnectedness between the gut microbiome and host
metabolism has led to a paradigm shift in the study of metabolic diseases such as obesity …

Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of
chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the …

Type 2 diabetes mellitus (T2DM) associated non-alcoholic fatty liver disease (NAFLD) is the
fourth-leading cause of death. Hyperglycemia induces various complications, including …

The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …